Welcome to our dedicated page for Albemarle SEC filings (Ticker: ALB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Locating lithium volume forecasts or bromine pricing clauses in Albemarle’s 250-page reports can feel overwhelming. Stock Titan solves this by turning Albemarle’s complex SEC filings into clear, actionable insight—so you can focus on decisions, not document hunts.
Every filing is here in real time, from the Albemarle annual report 10-K simplified to the latest Albemarle quarterly earnings report 10-Q filing. Our AI surfaces segment-level EBITDA, capex plans for Chilean brine assets, and risk factors tied to lithium prices—without scrolling through footnotes. Need to monitor management moves? Receive instant alerts on Albemarle insider trading Form 4 transactions and track Albemarle Form 4 insider transactions real-time to spot buying or selling patterns ahead of material events.
Common questions are answered in-line: “How do I understand Albemarle SEC documents with AI?” Simply open any 8-K; our summary explains the supply-contract or environmental update in plain English. Curious about leadership pay? The Albemarle proxy statement executive compensation section highlights equity awards and performance metrics. Need context on sudden news? The platform links each Albemarle 8-K material events explained summary to prior disclosures, giving you timeline clarity in seconds.
Whether you’re reviewing catalysts margins, tracking debt covenants, or comparing Albemarle earnings report filing analysis across quarters, Stock Titan provides:
- AI-powered summaries that explain every form in simple terms
- Real-time EDGAR updates across 10-K, 10-Q, 8-K, S-8, and more
- Instant access to Albemarle executive stock transactions Form 4
- Downloadable data tables for quick model inputs
Spend less time parsing disclosures and more time understanding how Albemarle converts critical resources into shareholder value.
Albemarle Corporation reported a change in its board leadership. On December 8, 2025, director Dean L. Seavers submitted his resignation from the company’s Board of Directors and from all committees on which he serves, with the resignation to become effective on December 12, 2025. The company stated that his decision to resign is not related to any disagreement regarding Albemarle’s operations, policies, or practices. This indicates a governance change without an identified dispute over the company’s direction or management approach.
Capital Research Global Investors filed an amended Schedule 13G reporting beneficial ownership in Albemarle Corp. (ALB).
CRGI beneficially owns 2,111,525 shares of Albemarle common stock, representing 1.8% of the 119,794,457 shares believed outstanding, with an event date of 09/30/2025. It has sole voting and sole dispositive power over 2,111,525 shares and no shared power. The reported position includes 4,620,404 Convertible Preferred Stocks that represent 2,111,525 common shares. CRGI certifies the securities were acquired and are held in the ordinary course and not to influence control.
Albemarle Corporation (ALB) reported insider equity activity by its Chief Financial Officer. On 11/06/2025, 1,953 Restricted Stock Units (RSUs) converted to common stock (code M) at $0. To cover taxes from the vesting, 854 shares were withheld at $91.26 (code F). After these transactions, the officer directly owned 12,210 common shares.
The filing notes that each RSU converts into one share, and 1,953 RSUs remain outstanding and will vest 100% on 11/06/2026, subject to the award terms.
State Street Corporation filed a Schedule 13G reporting beneficial ownership of 5,617,617 shares of Albemarle Corp (ALB) common stock, representing 4.8% of the class as of the event date 09/30/2025.
The filing lists shared voting power over 3,726,795 shares and shared dispositive power over 5,617,176 shares, with no sole voting or dispositive power. State Street is identified as a holding company (HC), with investment adviser affiliates including SSGA entities. The certification states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control.
Albemarle (ALB) reported a proposed insider sale under Rule 144. The notice covers up to 38,531 common shares, with an aggregate market value of $3,733,079.56, to be executed through Merrill Lynch. The approximate sale date listed is 11/07/2025.
The shares were acquired as stock awards on 08/09/2019 from Albemarle. A baseline figure shows 117,697,540 shares outstanding. This filing is a notice of potential sales by an affiliate and does not itself execute a transaction.
Albemarle Corporation (ALB) reported a narrower quarterly loss as lithium markets remain weak but cash generation improved. For Q3, net sales were $1,307.8 million versus $1,354.7 million a year ago. Operating loss was $216.986 million, including a non-cash $181.1 million goodwill impairment tied to the Refining Solutions reporting unit. Net loss attributable to common shareholders was $202.4 million, or $1.72 per share, compared with a $1.1107 billion loss, or $9.45 per share, last year.
Gross profit improved to $117.6 million from a loss last year as cost actions and lower inventory charges helped. Equity income from unconsolidated investments contributed $60.6 million, led by Windfield. Year to date, operating cash flow rose to $893.8 million, capital expenditures fell to $434.4 million, and cash ended at $1.932 billion. The company recorded $350 million of deferred revenue from a customer for future deliveries of spodumene and lithium salts over five years.
Inventory valuation adjustments declined to $11.1 million as of September 30, 2025. Shares outstanding were 117,697,540 as of October 29, 2025.
Albemarle Corporation furnished an update on its business by issuing a press release reporting results for the third quarter ended September 30, 2025. The release is provided as Exhibit 99.1 to an Item 2.02 current report. The Company will host an analyst and media teleconference on November 6, 2025, with a webcast available at www.albemarle.com. The information in this report, including Exhibit 99.1, is furnished and not deemed filed under the Exchange Act.
Albemarle Corporation (ALB): Schedule 13G/A (Amendment No. 2) discloses that Franklin Resources, Inc. and affiliates reported beneficial ownership of 6,853,257 common shares, representing 5.7% of the class as of September 30, 2025. The filing states this includes 3,551,809 shares issuable on conversion of debt securities under Rule 13d‑3(d)(1)(i).
Franklin Advisers, Inc. reports 6,088,726 shares, or 5.0%, with sole voting and dispositive power over that amount. For Franklin Resources, the filing lists sole voting power 6,463,983 and shared voting power 62,493; sole dispositive power 6,790,597 and shared dispositive power 62,660. Charles B. Johnson and Rupert H. Johnson, Jr. each report 0 shares.
The certification states the securities were acquired and are held in the ordinary course of business and not for the purpose or effect of changing or influencing control.
Albemarle (ALB) Form 4: The company’s General Counsel & Secretary reported a sale of 172 shares of common stock on 10/24/2025 at $105 per share (Transaction Code: S). The filing states the trade was executed under a Rule 10b5-1 trading plan adopted on March 13, 2025, prior to the individual becoming an executive officer. Following the transaction, the insider directly holds 11,483 shares.
Albemarle (ALB) agreed to sell and contribute its Ketjen business into a new structure with KPS affiliates, receiving an estimated $536 million in cash at closing and retaining Rollover Equity initially representing a 49% interest in Holdco. The purchase price framework values the purchased shares at $800.0 million less the value ascribed to the contributed shares, subject to customary closing adjustments. The transaction is expected to close in the first half of 2026, subject to regulatory approvals and other conditions.
Separately, Ketjen agreed to sell its interest in Eurecat S.A. for €105 million (approximately $125 million). Albemarle expects approximately $660 million in aggregate cash proceeds from both transactions, to be used for debt reduction and general corporate purposes. Albemarle also expects a non-cash goodwill impairment charge of $181.5 million in Q3 2025 tied to the Refining Solutions reporting unit.
The agreement includes an Outside Date of April 30, 2026 and a potential $32.5 million termination fee payable to Albemarle by the purchaser under specified circumstances.